Publisher Correction: RUNX2 inhibitor CADD522 improves bone microarchitecture and lipid metabolism in post-menopausal bone loss.
Ersek A, Kim MS, Suelzu C, Piec I, Matsangos A, Nurmemmedov E, Bull EC, Bartlett T, Dunn R, Dick JR, Lapidus R, Copeman DM, Tang JCY, Crichton PG, Pontifex MG, Fraser WD, Horwood NJ, Passaniti A, Green D
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.